Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Prexasertib · ACR-368, LY-2606368

Small molecule · Inhibitor of checkpoint kinase 1 (CHEK1) · developed by Eli Lilly and Company

Phase 2 Most advanced trial
1 Registered trials

What is Prexasertib?

Prexasertib is a small-molecule inhibitor of checkpoint kinase 1 (CHK1) that prevents DNA repair and promotes genomic instability and apoptosis in tumor cells. It is studied in head and neck squamous cell carcinoma and may potentiate the cytotoxicity of DNA-damaging chemotherapeutic agents.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
ACR-368, LY-2606368
Drug type
Small molecule
Targets
checkpoint kinase 1 (CHEK1)
Mechanism
Inhibitor of checkpoint kinase 1 (CHEK1)
Pathways
DNA repair, cell cycle checkpoint control, apoptosis
Therapy area
Oncology
Developer
Eli Lilly and Company
In trials of
ACRV
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
820NH671E6

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06597565 Phase 2 Head and Neck Squamous Cell Carcinoma Recruiting ACRV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Head and Neck Squamous Cell Carcinoma

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.